F10 and Stroke: Direct factor Xa (FXa) inhibitors are increasingly being used as anticoagulant therapy for the management of thromboembolic disorders such as prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, prophylaxis/treatment of venous thromboembolism, and thromboprophylaxis following hip or knee replacement surgery.